These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1349 related articles for article (PubMed ID: 33879103)

  • 1. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
    Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
    Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
    Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
    Front Immunol; 2020; 11():590618. PubMed ID: 33391264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
    J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
    Alessandrino F; Williams K; Nassar AH; Gujrathi R; Silverman SG; Sonpavde G; Shinagare AB
    Radiology; 2020 Jun; 295(3):572-580. PubMed ID: 32228295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W; Zhu D; Wang C; Zhu Y
    Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.